Literature DB >> 25895587

Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population.

S Jeson Sangaralingham1, Paul M McKie2, Tomoko Ichiki2, Christopher G Scott2, Denise M Heublein2, Horng H Chen2, Kent R Bailey2, Margaret M Redfield2, Richard J Rodeheffer2, John C Burnett2.   

Abstract

C-type natriuretic peptide (CNP) is an endothelium-derived peptide that is released as a protective mechanism in response cardiovascular injury or disease. However, no studies have investigated circulating CNP, identifying clinical factors that may influence CNP and its relationship to cardiovascular disease in the general population. We studied 1841 randomly selected subjects from Olmsted County, MN (mean age, 63±11 years; 48% men). Plasma CNP was measured by a well-established radioimmunoassay and echocardiography, clinical characterization, and detailed medical record review were performed. We report that CNP circulates at various concentrations (median, 13 pg/mL), was unaffected by sex, was weakly associated by age, and that highest quartile of CNP identified a high-risk phenotype. Subjects with CNP in the highest quartile were associated with increased risk of myocardial infarction (multivariable-adjusted hazard ratio, 1.51; 95% confidence interval, 1.09-2.09; P=0.01) but not heart failure, cerebrovascular accidents, or death during a follow-up of 12 years. Addition of the highest quartile of CNP to clinical variables led to a modest increase in the integrated discrimination improvement for risk of myocardial infarction. In a large community-based cohort, elevated circulating CNP identified a high-risk phenotype that included cardiovascular comorbidities and left ventricular dysfunction, and provided evidence that highest concentrations of CNP potentially has prognostic value in predicting future risk of myocardial infarction. Together, these data from the general population highlight the potential value of CNP and support the need for additional studies to evaluate whether mechanisms regulating CNP could improve outcomes.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  C-type natriuretic peptide; biological markers; cardiovascular diseases; endothelium; myocardial infarction

Mesh:

Substances:

Year:  2015        PMID: 25895587      PMCID: PMC4433426          DOI: 10.1161/HYPERTENSIONAHA.115.05366

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  35 in total

1.  Impact of age and sex on plasma natriuretic peptide levels in healthy adults.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Eric P Leip; Emelia J Benjamin; Peter W F Wilson; Patrice Sutherland; Torbjorn Omland; Ramachandran S Vasan
Journal:  Am J Cardiol       Date:  2002-08-01       Impact factor: 2.778

2.  Different compartmentation of responses to brain natriuretic peptide and C-type natriuretic peptide in failing rat ventricle.

Authors:  Lise Román Moltzau; Jan Magnus Aronsen; Silja Meier; Jonas Skogestad; Øivind Ørstavik; Gustav B Lothe; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Eirik Qvigstad
Journal:  J Pharmacol Exp Ther       Date:  2014-07-14       Impact factor: 4.030

3.  Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications.

Authors:  Tomoko Ichiki; John A Schirger; Brenda K Huntley; Frank V Brozovich; Joseph J Maleszewski; Sharon M Sandberg; S Jeson Sangaralingham; Soon J Park; John C Burnett
Journal:  J Mol Cell Cardiol       Date:  2014-08-09       Impact factor: 5.000

4.  Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study.

Authors:  Paul M McKie; Alessandro Cataliotti; S Jeson Sangaralingham; Tomoko Ichiki; Valentina Cannone; Kent R Bailey; Margaret M Redfield; Richard J Rodeheffer; John C Burnett
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

Review 5.  The role of natriuretic peptides in cardioprotection.

Authors:  Toshio Nishikimi; Nobuyo Maeda; Hiroaki Matsuoka
Journal:  Cardiovasc Res       Date:  2005-11-10       Impact factor: 10.787

6.  C-type natriuretic peptide induces redifferentiation of vascular smooth muscle cells with accelerated reendothelialization.

Authors:  K Doi; T Ikeda; H Itoh; K Ueyama; K Hosoda; Y Ogawa; J Yamashita; T H Chun; M Inoue; K Masatsugu; N Sawada; Y Fukunaga; T Saito; M Sone; K Yamahara; H Kook; M Komeda; M Ueda; K Nakao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-06       Impact factor: 8.311

7.  Natriuretic peptide system gene expression in human coronary arteries.

Authors:  Victor H Casco; John P Veinot; Mercedes L Kuroski de Bold; Roy G Masters; Michelle M Stevenson; Adolfo J de Bold
Journal:  J Histochem Cytochem       Date:  2002-06       Impact factor: 2.479

8.  Plasma brain natriuretic peptide concentration: impact of age and gender.

Authors:  Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

9.  Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction.

Authors:  Dirk J Lok; Ijsbrand T Klip; Adriaan A Voors; Sjoukje I Lok; Pieta W Bruggink-André de la Porte; Hans L Hillege; Tiny Jaarsma; Dirk J van Veldhuisen; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2014-07-31       Impact factor: 15.534

10.  Endothelial C-type natriuretic peptide maintains vascular homeostasis.

Authors:  Amie J Moyes; Rayomand S Khambata; Inmaculada Villar; Kristen J Bubb; Reshma S Baliga; Natalie G Lumsden; Fang Xiao; Paul J Gane; Anne-Sophie Rebstock; Roberta J Worthington; Michela I Simone; Filipa Mota; Fernando Rivilla; Susana Vallejo; Concepción Peiró; Carlos F Sánchez Ferrer; Snezana Djordjevic; Mark J Caulfield; Raymond J MacAllister; David L Selwood; Amrita Ahluwalia; Adrian J Hobbs
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

View more
  15 in total

1.  Relaxing With C-Type Natriuretic Peptide, the Guanylyl Cyclase B Receptor, and Pericytes.

Authors:  S Jeson Sangaralingham; John C Burnett
Journal:  Circulation       Date:  2018-07-31       Impact factor: 29.690

Review 2.  Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.

Authors:  Ruth Hsiao; Barry Greenberg
Journal:  Curr Heart Fail Rep       Date:  2016-08

Review 3.  Physiological and Pathophysiological Effects of C-Type Natriuretic Peptide on the Heart.

Authors:  Akihiro Yasoda
Journal:  Biology (Basel)       Date:  2022-06-14

Review 4.  Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF.

Authors:  Speranza Rubattu; Filippos Triposkiadis
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

5.  Natriuretic Peptide Receptor B modulates the proliferation of the cardiac cells expressing the Stem Cell Antigen-1.

Authors:  Stéphanie Rignault-Clerc; Christelle Bielmann; Lucas Liaudet; Bernard Waeber; François Feihl; Nathalie Rosenblatt-Velin
Journal:  Sci Rep       Date:  2017-02-09       Impact factor: 4.379

6.  Increased circulating bioactive C-type natriuretic peptide is associated with reduced heart rate variability in patients with chronic kidney disease.

Authors:  Lulu Wang; Wenjin Liu; Yanting Yu; Lei Jiang; Junwei Yang
Journal:  BMC Nephrol       Date:  2018-03-05       Impact factor: 2.388

7.  A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure.

Authors:  Rika Kawakami; Candace Y W Lee; Christopher Scott; Kent R Bailey; John A Schirger; Horng H Chen; Sherry L Benike; Valentina Cannone; Fernando L Martin; S Jeson Sangaralingham; Tomoko Ichiki; John C Burnett
Journal:  Clin Pharmacol Ther       Date:  2018-01-11       Impact factor: 6.875

Review 8.  C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature.

Authors:  Amie J Moyes; Adrian J Hobbs
Journal:  Int J Mol Sci       Date:  2019-05-08       Impact factor: 5.923

9.  Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure.

Authors:  Xiao Ma; Yang Chen; Shawn H Reginauld; Christopher G Scott; Seethalakshmi R Iyer; Jacob J Schaefer; Tomoko Ichiki; Horng H Chen; Andrew D Rule; John C Burnett; S Jeson Sangaralingham
Journal:  JACC Heart Fail       Date:  2021-07-07       Impact factor: 12.544

10.  C-Type Natriuretic Peptide (CNP) Inhibition of Interferon-γ-Mediated Gene Expression in Human Endothelial Cells In Vitro.

Authors:  Amy Day; Zoe Jameson; Carolyn Hyde; Bigboy Simbi; Robert Fowkes; Charlotte Lawson
Journal:  Biosensors (Basel)       Date:  2018-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.